Custom service

Plant Cell based VLP Production

Particles grown in Nicotiana benthamiana, in weeks and at agricultural scale.

Host: Nicotiana benthamiana, transient agroinfiltration; glycoengineered lines availableVLP types: Non-enveloped and enveloped custom particlesScale: Grams of purified particle per campaign, scalable further

Transient expression in Nicotiana benthamiana is the fastest route from a construct to a large quantity of assembled particle. Agrobacterium delivers the expression vectors to leaves, the plant produces the proteins within five to seven days, and the scale-up path is agricultural rather than bioreactor-based — more plants, not bigger tanks. A plant-produced VLP vaccine has been authorised for human use, which settles the regulatory question that used to shadow the platform.

The workflow starts with vector design: the structural genes placed under strong plant promoters, sometimes split between two constructs to balance component ratios, with the agrobacterium strains and infiltration ratios optimised for particle assembly. Harvest at five to seven days post-infiltration, when particle yield peaks ahead of tissue degradation.

Purification from leaf tissue differs from cell culture in one important way: the starting material is full of phenolics, pigments and plant proteins, and the purification has to remove them. Clarification with antioxidant buffers, PEG or density-based steps, and particle purification by SEC or chromatography follow, with the same particle-level QC as any other VLP system — TEM, composition, glycan profile and antigenicity.

Plant VLP production is chosen when quantity requirements exceed what cell culture supplies economically, when low endotoxin matters for immunisation or in vivo work, and when a fast path from construct to grams is the deciding factor.

It is not the route for particles whose antigenicity depends on mammalian glycosylation without engineered lines, and timelines include plant growth, which is less compressible than cell culture scheduling.

Batches are released with TEM morphology and count, protein composition by mass spectrometry, N-glycan profile including xylose and fucose content, antigenicity where a readout exists, and confirmation that endotoxin is absent by the production system.

Service Highlights

  • Fast scale-up. Grams of particle within weeks, with a scale path that adds plants rather than bioreactor volume.
  • No fermentation infrastructure. Production capacity scales with greenhouse space, which changes the cost structure for large quantities.
  • Plant-type glycans. N-glycans carry beta-1,2-xylose and alpha-1,3-fucose; glycoengineered lines without them are available where that matters.
  • Dual-construct balance. Structural genes split across agrobacterium strains with infiltration ratios tuned for particle stoichiometry.
  • Low-endotoxin product. Plant systems carry no endotoxin, which simplifies QC for immunisation and in vivo work.
  • Regulatory precedent. A plant-produced VLP vaccine has been authorised, giving the platform a documented regulatory path.

How the work runs

  1. Vector design

    Structural genes under plant promoters, split across constructs where component balance requires it.

  2. Agrobacterium preparation

    Strains transformed and infiltration suspensions prepared at the designed ratios.

  3. Infiltration and expression

    Vacuum infiltration of Nicotiana benthamiana leaves; expression monitored over five to seven days.

  4. Harvest and extraction

    Leaf tissue harvested at peak particle yield and homogenised in antioxidant extraction buffer.

  5. Purification

    Clarification, concentration, plant protein and pigment removal, and particle purification by SEC or gradient.

  6. QC

    TEM morphology and count, protein composition, N-glycan profile, antigenicity, endotoxin absent by nature.

Specifications & timeline

Host
Nicotiana benthamiana, transient agroinfiltration; glycoengineered lines available
VLP types
Non-enveloped and enveloped custom particles
Scale
Grams of purified particle per campaign, scalable further
QC
TEM, LC-MS, N-glycan profile, antigenicity
Timeline
4–8 weeks per construct

Related Products

Next step

Tell us the target, we will tell you what is feasible

Send the sequence, assay format and sensitivity you need. You will get a technical assessment — recommended platform, timeline and the risks worth knowing before you commit budget.